The Predictive Value of Serum Histone Succinylation in Malignant Solid Tumors
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Malignant Tumors. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Serum Histone Succinylation: A Predictive Biomarker for Malignant Solid Tumors
Overview
In recent years, advances in protein post-translational modification (PTM) research have revealed histone succinylation as a novel epigenetic modification mechanism critically involved in tumor initiation, progression, and prognosis. Succinylation alters protein physicochemical properties and functions, thereby modulating cellular metabolism, proliferation, and apoptosis. Aberrant histone succinylation in tumor cells demonstrates significant correlations with tumor type, staging, and clinical outcomes, offering new avenues for early cancer diagnosis. This project utilizes blood serum samples to quantify histone succinylation levels through modification-specific antibody-based detection. Integrated with clinical data, this approach enables early, rapid, and accurate pan-cancer diagnosis, achieving tumor screening via a single-tube blood test. It represents a paradigm shift in precision oncology from "gene-driven" to "epigenetic-metabolic-driven" early detection.
Detailed description
Primary Objective To evaluate differential expression of serum histone succinylation between malignant solid tumor patients and healthy controls, thereby validating its early detection value.
Secondary Objectives
To determine correlations between serum histone succinylation levels and:
Tumor types Tumor stages
To statistically analyze associations of serum histone succinylation with:
Therapeutic efficacy (surgical intervention, radiotherapy, systemic therapy) Clinicopathological variables
Primary outcome measures
- Evaluate the positive rate of serum histone succinylation in patients with malignant solid tumors [Time frame: 2025.08.01-2026.12.31]
Secondary outcome measures (1)
- Define the relationship between histone succinylation modifications in serum and different tumor types as well as tumor staging [Time frame: 2025.08.01-2026.12.31]
Eligibility criteria
Inclusion criteria
Case Group:
- Aged ≥18 years, regardless of sex；
- Histologically or cytologically confirmed malignant solid tumors requiring subsequent anticancer therapy；
Control Group:
- Aged ≥18 years, regardless of sex；
- Non-cancer participants enrolled through health screenings；
Exclusion criteria
- Pregnant individuals；
- Individuals with serious mental disorders or communication barriers；
- Other conditions deemed by investigators to contraindicate study participation；
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07132606 · CHASE 016 · Chase 016